Michael Crowley, vice president of business development at PharmaForm, said: “We are very pleased to have been awarded this important contract and with our long relationship with Repros.
“Proellex will fill unmet medical needs and could be a blockbuster should it meet all clinical endpoints. It represents a great partnership and opportunity for both organizations.”